Showing 1,581 - 1,600 results of 100,232 for search '(( 5 point decrease ) OR ( 5 ((((nm decrease) OR (nn decrease))) OR (a decrease)) ))', query time: 1.62s Refine Results
  1. 1581
  2. 1582
  3. 1583
  4. 1584
  5. 1585
  6. 1586
  7. 1587

    ATP assay. by Dong Ma (584680)

    Published 2020
    Subjects:
  8. 1588
  9. 1589
  10. 1590
  11. 1591
  12. 1592

    Change in percentage of pO values ≤5 mmHg by Bernardino Clavo (3925)

    Published 2011
    “…</p> During ozone therapy, a decrease in percentage of pO values ≤5 mmHg at each measurement time-point was observed in the tumors of patients: = before ozone therapy; = after session #1 ( = 0.002); = 48 h after session #2 ( = 0.045); = after session #3 ( = 0.033). …”
  13. 1593
  14. 1594

    Lowering Melting Points in Asymmetrically Substituted Salen-Copper(II) Complexes Exhibiting Mesomorphic Behavior. Structure of the Mesogen Cu(5-hexyloxySalen) by Reinhard Paschke (553784)

    Published 2002
    “…In comparison with their symmetrical analogues, unsymmetrically substituted Cu−Salen complexes show mesophases with lowered melting points. For terminally substituted complexes, symmetrical ones (R<sup>1</sup> = R<sup>2</sup>) have only an S<sub>A</sub> phase, while for unsymmetrical alkoxy substitution a monotropic S<sub>E</sub> phase occurs and the melting temperature decreases with no loss in mesophase stability. …”
  15. 1595

    Lowering Melting Points in Asymmetrically Substituted Salen-Copper(II) Complexes Exhibiting Mesomorphic Behavior. Structure of the Mesogen Cu(5-hexyloxySalen) by Reinhard Paschke (553784)

    Published 2002
    “…In comparison with their symmetrical analogues, unsymmetrically substituted Cu−Salen complexes show mesophases with lowered melting points. For terminally substituted complexes, symmetrical ones (R<sup>1</sup> = R<sup>2</sup>) have only an S<sub>A</sub> phase, while for unsymmetrical alkoxy substitution a monotropic S<sub>E</sub> phase occurs and the melting temperature decreases with no loss in mesophase stability. …”
  16. 1596

    Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Stud... by Ken Ohta (727449)

    Published 2015
    “…Commonly reported AEs with tiotropium 5 μg, 2.5 μg and placebo were nasopharyngitis (48.2%, 44.7%, 42.1%), asthma (28.9%, 29.8%, 38.6%), decreased PEFR (15.8%, 7.9%, 21.1%), bronchitis (9.6%, 13.2%, 7.0%), pharyngitis (7.9%, 13.2%, 3.5%) and gastroenteritis (10.5%, 3.5%, 5.3%). …”
  17. 1597

    Decreased Sho levels in ScN2a-Sho cells. by Joel C. Watts (195735)

    Published 2011
    “…(<b>C</b>) Quantification of Sho levels in ScN2a-Sho-1 (<i>n</i> = 10) and ScN2a-Sho-2 (<i>n</i> = 5) subclones revealed a significant decrease of 40–45% compared to the uninfected parental cell line (<i>n</i> = 15) (***<i>P</i><0.001).…”
  18. 1598
  19. 1599
  20. 1600